This review assessed angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers for the prevention of atrial fibrillation. The authors concluded that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers appear to reduce atrial fibrillation, but the results differed amongst studies. An inadequate validity assessment and the combining of studies using different comparator treatments limits the robustness of the evidence.
Participants included in the review
Inclusion criteria were not defined in terms of the participants. The included studies were in individuals with hypertension, post myocardial infarction (MI) with and without left ventricular (LV) dysfunction, heart failure, and following cardioversion for AF. In the included studies, the LV ejection fraction (LVEF) ranged from 27 to 64 (reported in 6 studies) and the rate of AF in the control groups ranged from 2 to 64%.
Outcomes assessed in the review
Studies that assessed new or recurrent AF were eligible for inclusion. The included studies used different definitions of AF and different methods to diagnose AF: the methods ranged from an electrocardiogram once a year to extensive investigations, including daily event recording using Holter for 24 hours at 1, 6 and 12 months.
How were decisions on the relevance of primary studies made?
Two reviewers independently evaluated titles and two blinded reviewers independently selected studies. Any disagreements were resolved by consensus.
Assessment of study quality
The studies appear to have been assessed for blinding of the outcome assessment. The authors did not state how the validity assessment was performed.
Data extraction
The data were independently extracted in duplicate and any disagreements were resolved through consensus. For each treatment arm in each study, the numbers of patients with AF were extracted. Data were extracted for all patients in factorial studies. The authors of studies of ACEIs and ARBs that did not report data for AF were contacted for this information.
Methods of synthesis
How were the studies combined? Pooled relative risk reductions (RRRs) with 95% confidence intervals (CIs) were calculated using a random-effects model (DerSimonian and Laird); the studies were weighted by the sample size. For the main meta-analysis, singlecentre data for the occurrence of AF were used from one study that also reported results for hospitalisations due to AF. The potential for publication bias was assessed by considering the effect size in relation to the sample size.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared test. Separate meta-analyses were performed for ACEIs and ARBs separately, and for subgroups of studies of patients with different medical conditions (heart failure, hypertension, AF and post MI). The meta-analysis was repeated using data for hospitalisations due to AF for one study that also reported results for AF. Differences between the studies, with respect to duration of follow-up, study size and methods used to document AF, were also considered.
Results of the review
Eleven RCTs with a total of 56,308 patients were included.
In terms of study quality, in 7 studies the outcomes were assessed by blinded investigators; some other studies assessed outcomes by events committees.
ACEIs and ARBs significantly reduced the relative risk of developing AF compared with control by 28% (95% CI: 15, 40, p=0.0002). Statistically significant heterogeneity was found (p=0.0002).
AECIs and ARBs reduced AF by a similar amount: 28% (95% CI: 7, 44, p=0.01) for ACEIs and 29% (95% CI: 16, 40, p=0.0002) for ARBs. Statistically significant heterogeneity was found for both meta-analyses (both p<0.00001).
Treatment effects by medical condition.
Post MI (2 studies): the results were mixed. One study of patients with LV dysfunction found a significant reduction in AF with trandolapril for up to 4 years (RRR 0.52, 95% CI: 0.31, 0.87). The larger study, in patients with no heart failure, found no significant reduction in the risk of AF with 6 weeks of lisinopril compared with control (RRR 0.92, 95% CI: 0.83, 1.02).
Heart failure (4 studies): in patients with heart failure, ACEIs and ARBs significantly reduced the risk of AF by 44% (95% CI: 15, 63, p=0.007). All studies showed a significant reduction in AF but statistically significant heterogeneity was found (p=0.002).
In 3 studies the RRR appeared to increase with the severity of LV dysfunction: the RRR was 78% for 1 study of patients with severely impaired LV function (mean LVEF 26.7%), 23% for 1 study with mean LVEF 28%, and 18% for 1 study with mean LVEF 39%. The other study found a similar RRR in AF in patients with normal and impaired LV function.
Hypertension (3 studies): there was no significant reduction in AF with ACEIs and ARBs in patients with hypertension (RR 0.88, 95% CI: 0.66, 1.19, p=0.4). Statistically significant heterogeneity was found (p=0.001). Only the study of ARBs in patients with LV hypertrophy showed a significant reduction in the risk of AF.
Secondary prevention of AF after cardioversion (2 studies): most patients had hypertension and unimpaired LV function. There was a significantly reduction in AF with AECIs and ARBs in patients following cardioversion (RRR
